An Open-label Observational Safety Study of Colobreathe® (colistimethate sodium dry powder for inhalation) Compared with Other Inhaled Anti-pseudomonal Antibiotics in Cystic Fibrosis Patients Using Cystic Fibrosis Registries

27/11/2016
10/03/2020
EU PAS number:
EUPAS16395
Study
Finalised

ENCePP Code of conduct

No
Data sources

Data sources (types)

Disease registry
Use of a Common Data Model (CDM)

CDM mapping

No
Data quality specifications

Check conformance

Unknown

Check completeness

Unknown

Check stability

Unknown

Check logical consistency

Unknown
Data characterisation

Data characterisation conducted

No